Litcius/Paper detail

Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial

Nisa Laohapojanart, Chaveewan Ratanajamit, Kamon Kawkitinarong, Teerapol Srichana

2021Pulmonary Pharmacology & Therapeutics24 citationsDOI

Topics & Concepts

MedicinePyrazinamideDry-powder inhalerIsoniazidLevofloxacinRifampicinCulture conversionInternal medicineTuberculosisPlaceboRandomized controlled trialAdverse effectSputumIntention-to-treat analysisSurgeryAntibioticsInhalerPathologyAsthmaMicrobiologyAlternative medicineBiologyInhalation and Respiratory Drug DeliveryTuberculosis Research and EpidemiologyAsthma and respiratory diseases
Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial | Litcius